Long-Term Systemic Expression and Cross-Correction Ability of HMI-203, Investigational Gene Therapy Candidate for Mucopolysaccharidosis Type II (MPS II), or Hunter Syndrome

Patel K, Smith L, Gingras J, Tzianabos A, et al. ASHG 2021.